跳至主要内容
临床试验/IRCT20221128056654N1
IRCT20221128056654N1招募中1 期

Comparison of the efficacy and adverse effects of dexmedetomidine and haloperidol in reducing the symptoms of Deliriumin patients in Intensive Care Unit - A Randomized Clinical Trial.

Esfahan University of Medical Sciences0 个研究点目标入组 74 人开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
入组人数
74

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Patients who are diagnosed with delirium based on DSM5 criteria.
  • Patients who have not received non-pharmacological treatments to control symptoms.
  • 5=ICDSC ? RASS=+1
  • Not being intubated or extubated for more than 24 hours
  • Hospitalization in ICU for non-surgical reasons

排除标准

  • Patients who receive drugs other than dexmedetomidine or haloperidol for the treatment of delirium (such as other antipsychotics and midazolam)
  • Receiving dexmedetomidine or haloperidol within 72 hours before entering the study
  • Patients with a history of drug sensitivity to dexmedetomidine or haloperidol.
  • Patients with a history of long QTc (<500 ms)
  • Patients with dementia, Parkinson's, malignant neuroleptic syndrome, patients with a history of major psychiatric disorders such as bipolar and schizophrenia, addiction to various drugs and stimulants.
  • Women during breastfeeding and pregnancy
  • Unwillingness of the patient or family to participate in the study
  • Severe forms of vision and hearing

研究者

相似试验

Investigation of Dexmedetomidine and Haloperidol in... | 临床试验